Massive data study tests if Real-World records can mimic Gold-Standard heart trials
NCT ID NCT07088718
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 29 times
Summary
This completed study looked at whether information from everyday healthcare claims can accurately predict the results of a large clinical trial (SURPASS-CVOT) that compared two diabetes drugs, tirzepatide and dulaglutide, for heart safety. Researchers analyzed records from over 44,000 people with type 2 diabetes and heart disease. The goal was not to test a new treatment, but to learn how to use real-world data more reliably for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.